{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T10:00:40Z","timestamp":1785060040924,"version":"3.55.0"},"reference-count":51,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2023,6,26]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:p>\n                  <jats:bold>Objective<\/jats:bold> Interstitial lung disease (ILD) is an important cause of mortality in some patients with rheumatoid arthritis (RA). Patient-level factors may predict which patients with RA are at the highest risk of developing ILD and are therefore candidates for screening for this complication of the underlying disease.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methods<\/jats:bold> A systematic literature review was performed using PubMed, Embase and Scopus over a 10-year period up to July 2021. Publications reporting patient-level factors in patients with RA with and without ILD that were assessed before development of ILD (or were unchanged over time and therefore could be extrapolated to before development of ILD) were retrieved for assessment of evidence. Genetic variation in <jats:italic>MUC5B<\/jats:italic> and treatment with methotrexate were not included in the assessment of evidence because these factors have already been widely investigated for association with ILD.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results<\/jats:bold> We found consistent associations of age, sex, smoking status and autoantibodies with development of ILD. For biomarkers such as Krebs von den Lungen 6, which have been shown to be diagnostic for ILD, there were no publications meeting criteria for this study.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusions<\/jats:bold> This analysis provides an initial step in the identification of patient-level factors for potential development of a risk algorithm to identify patients with RA who may be candidates for screening for ILD. The findings represent a useful basis for future research leading to an improved understanding of the disease course and improved care for patients with RA at risk of development and progression of ILD.<\/jats:p>","DOI":"10.1136\/rmdopen-2023-003059","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T13:00:46Z","timestamp":1690549246000},"page":"e003059","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9866-0124","authenticated-orcid":false,"given":"Eric L.","family":"Matteson","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-3161","authenticated-orcid":false,"given":"Marco","family":"Matucci-Cerinic","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy"},{"name":"Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[{"name":"Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, German Center for Lung Research, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-1131","authenticated-orcid":false,"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4814-0307","authenticated-orcid":false,"given":"Philippe","family":"Dieud\u00e9","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Bichat Hospital APHP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7429-8482","authenticated-orcid":false,"given":"Paul","family":"Emery","sequence":"additional","affiliation":[{"name":"Leeds NIHR BRC, Leeds Teaching Hospitals NHS Trust, Leeds, UK"},{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Allanore","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, APHP, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1479-5302","authenticated-orcid":false,"given":"Janet","family":"Pope","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, St Joseph's Hospital, Western University, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[{"name":"DIvision of Rheumatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"2025090313305330000_9.3.e003059.1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu165"},{"key":"2025090313305330000_9.3.e003059.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq035"},{"key":"2025090313305330000_9.3.e003059.3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.semarthrit.2016.10.007","article-title":"Mortality profile of patients with rheumatoid arthritis in France and its change in 10 years","volume":"46","author":"Avouac","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313305330000_9.3.e003059.4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","article-title":"Impaired quality of life in systemic sclerosis and patient perception of the disease: A large International survey","volume":"46","author":"Frantz","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313305330000_9.3.e003059.5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.autrev.2017.09.010","article-title":"Humanistic and cost burden of systemic sclerosis: A review of the literature","volume":"16","author":"Fischer","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2025090313305330000_9.3.e003059.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211138"},{"key":"2025090313305330000_9.3.e003059.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.27405"},{"key":"2025090313305330000_9.3.e003059.8","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.517"},{"key":"2025090313305330000_9.3.e003059.9","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2007.59"},{"key":"2025090313305330000_9.3.e003059.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003132","article-title":"Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study","volume":"3","author":"Hozumi","year":"2013","journal-title":"BMJ Open"},{"key":"2025090313305330000_9.3.e003059.11","first-page":"155","article-title":"Up-to-date information on rheumatoid arthritis-associated interstitial lung disease","volume":"9","author":"Suda","year":"2015","journal-title":"Clin Med Insights Circ Respir Pulm Med"},{"key":"2025090313305330000_9.3.e003059.12","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0011-2021","article-title":"Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management","volume":"30","author":"Kadura","year":"2021","journal-title":"Eur Respir Rev"},{"key":"2025090313305330000_9.3.e003059.13","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600718080"},{"key":"2025090313305330000_9.3.e003059.14","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199805)41:5<817::AID-ART7>3.0.CO;2-S"},{"key":"2025090313305330000_9.3.e003059.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801562"},{"key":"2025090313305330000_9.3.e003059.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1216076"},{"key":"2025090313305330000_9.3.e003059.17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The Muc5B promoter polymorphism and Telomere length in patients with chronic hypersensitivity Pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025090313305330000_9.3.e003059.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.20018"},{"key":"2025090313305330000_9.3.e003059.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.11223"},{"key":"2025090313305330000_9.3.e003059.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220698"},{"key":"2025090313305330000_9.3.e003059.21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"key":"2025090313305330000_9.3.e003059.22","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/rheumatology\/kez337","article-title":"Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313305330000_9.3.e003059.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"2025090313305330000_9.3.e003059.24","unstructured":"Centre for Evidence Based Medicine . Critical appraisal of Prognostic studies. 2022. Available: https:\/\/www.cebm.net\/wp-content\/uploads\/2014\/04\/cebm-prognosis-worksheet.pdf"},{"key":"2025090313305330000_9.3.e003059.25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04846-1"},{"key":"2025090313305330000_9.3.e003059.26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1513\/AnnalsATS.202006-590OC","article-title":"Autoantibody Seropositivity and risk for interstitial lung disease in a prospective male-predominant rheumatoid arthritis cohort of U.S","volume":"18","author":"Natalini","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025090313305330000_9.3.e003059.27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.12659\/MSM.890880","article-title":"A retrospective study of clinical characteristics of interstitial lung disease associated with rheumatoid arthritis in Chinese patients","volume":"21","author":"Wang","year":"2015","journal-title":"Med Sci Monit"},{"key":"2025090313305330000_9.3.e003059.28","doi-asserted-by":"crossref","unstructured":"Klester E , Klester K , Shoykhet Y , et al . Risk factors of interstitial lung diseases in patients with rheumatoid arthritis. ERS International Congress 2019 abstracts; September 28, 2019:Suppl doi:10.1183\/13993003.congress-2019.PA1365","DOI":"10.1183\/13993003.congress-2019.PA1365"},{"key":"2025090313305330000_9.3.e003059.29","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3904\/kjim.2016.349","article-title":"Clinical characteristics associated with occurrence and poor prognosis of interstitial lung disease in rheumatoid arthritis","volume":"34","author":"Yang","year":"2019","journal-title":"Korean J Intern Med"},{"key":"2025090313305330000_9.3.e003059.30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017088","article-title":"High-resolution computed tomography of the lung in patients with rheumatoid arthritis: prevalence of interstitial lung disease involvement and determinants of abnormalities","volume":"98","author":"Salaffi","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025090313305330000_9.3.e003059.31","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-eular.1993","article-title":"Sat0030 a novel association between anti-Carbamylated antibodies and interstitial lung disease in patients with rheumatoid arthritis","volume":"79","author":"Castellanos-Moreira","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090313305330000_9.3.e003059.32","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201411-1950OC"},{"key":"2025090313305330000_9.3.e003059.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033133","article-title":"Association of human Leukocyte antigen with interstitial lung disease in rheumatoid arthritis: a protective role for shared EPITOPE","volume":"7","author":"Furukawa","year":"2012","journal-title":"PLoS One"},{"key":"2025090313305330000_9.3.e003059.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203160"},{"key":"2025090313305330000_9.3.e003059.35","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-eular.2083","article-title":"Thu0106 identification of markers associated with the occurrence of interstitial lung disease in rheumatoid arthritis patients","volume":"75","author":"Juge","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090313305330000_9.3.e003059.36","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.reuma.2019.05.007","article-title":"Development of a risk indicator score for the identification of interstitial lung disease in patients with rheumatoid arthritis","volume":"17","author":"Paulin","year":"2021","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"2025090313305330000_9.3.e003059.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092449","article-title":"Anti-cyclic Citrullinated peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis","volume":"9","author":"Yin","year":"2014","journal-title":"PLoS ONE"},{"key":"2025090313305330000_9.3.e003059.38","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200863"},{"key":"2025090313305330000_9.3.e003059.39","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: A prospective cohort study","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090313305330000_9.3.e003059.40","doi-asserted-by":"crossref","first-page":"e482","DOI":"10.1097\/RHU.0000000000001552","article-title":"Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: post hoc analysis from 21 clinical trials","volume":"27","author":"Citera","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"2025090313305330000_9.3.e003059.41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150224"},{"key":"2025090313305330000_9.3.e003059.42","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0583-4"},{"key":"2025090313305330000_9.3.e003059.43","doi-asserted-by":"publisher","DOI":"10.1007\/s10165-009-0170-4"},{"key":"2025090313305330000_9.3.e003059.44","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02314-2016","article-title":"Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis","volume":"49","author":"Juge","year":"2017","journal-title":"Eur Respir J"},{"key":"2025090313305330000_9.3.e003059.45","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s40744-021-00288-x","article-title":"Serum KL-6, Ca19-9, Ca125 and CEA are diagnostic biomarkers for rheumatoid arthritis-associated interstitial lung disease in the Chinese population","volume":"8","author":"Zheng","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025090313305330000_9.3.e003059.46","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232978","article-title":"Improving risk-stratification of rheumatoid arthritis patients for interstitial lung disease","volume":"15","author":"Avouac","year":"2020","journal-title":"PLoS One"},{"key":"2025090313305330000_9.3.e003059.47","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1007\/s10067-021-05585-y","article-title":"Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and Prognostic factors for rheumatoid arthritis-associated interstitial lung disease","volume":"40","author":"Fotoh","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025090313305330000_9.3.e003059.48","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1080\/14397595.2021.1879346","article-title":"Annual variation rate of KL-6 for predicting acute exacerbation in patients with rheumatoid arthritis-associated interstitial lung disease","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"2025090313305330000_9.3.e003059.49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229997","article-title":"Prognostic role of blood KL-6 in rheumatoid arthritis-associated interstitial lung disease","volume":"15","author":"Kim","year":"2020","journal-title":"PLoS One"},{"key":"2025090313305330000_9.3.e003059.50","first-page":"6813","article-title":"The anti-Mutated Citrullinated Vimentin antibody as a potential Predictor for rheumatoid arthritis associated interstitial lung diseases","volume":"9","author":"Tian","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"2025090313305330000_9.3.e003059.51","doi-asserted-by":"crossref","DOI":"10.1177\/11795441211028747","article-title":"Interstitial lung disease and its associations in rheumatoid arthritis: data from a district general hospital in Sri Lanka","volume":"14","author":"Wickrematilake","year":"2021","journal-title":"Clin Med Insights Arthritis Musculoskelet Disord"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:31:03Z","timestamp":1756931463000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":51,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,7,28]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/rmdopen-2023-003059"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003059","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}